Latest News

Big multiple sclerosis breakthrough: Phase 1 trial safely resets patients' immune systems and reduces attack on myelin protein

A phase 1 clinical trial for the first treatment to reset the immune system of multiple sclerosis (MS) patients showed the therapy was safe and dramatically reduced patients' immune systems' reactivity to myelin by 50 to 75 percent. The therapy used billions of patients' own specially processed blood cells to create tolerance to myelin, the insulating layer that forms around nerves. In MS, the immune system attacks myelin. The approach left the normal immune system intact.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Zebrafish Model of a Learning and Memory Disorder Shows Better Way to Target Treatment

  • Role of emergency contact is mistaken for advance directive

  • More evidence that sleep apnea is hurting your brain

  • More needed to protect our sportspeople from brain injury, say experts

  • Babies born in winter start crawling earlier than those born in summer

  • Teachers risk role confusion on Facebook

  • Structure of enzyme seen as target for ALS drugs

  • Study reveals profile of patients most likely to delay hospice enrollment until final days of life

  • U.S. military makes progress with sexual assault training, but more can be done

  • Compound protects brain cells after traumatic brain injury

  •